HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….
-
-
WHO recommended long-acting cabotegravir for HIV prevention
On Jul. 28, 2022, the World Health Organization (WHO) released new guidelines for the use of long-acting injectable…
-
Cell by cell, scientists building a high-resolution map of brain changes in Alzheimer’s disease
On Jul. 28, 2022, the Allen Institute announced a newly released dataset of 1.2M cells from brain donors…
-
BD, CerTest Biotec announced commercial launch of Monkeypox test
On Jul. 27, 2022, BD (Becton, Dickinson) announced their newly developed molecular polymerase chain reaction (PCR) test for…
-
Pfizer and BioNTech announced clinical trial of next-generation vaccine candidate based on enhanced spike protein design
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
-
Biotechnology | CDC | Disease | Environmental | Therapeutics
Bacteria that causes rare disease Melioidosis discovered in U.S. environmental samples
On Jul. 27, 2022, the Centers for Disease Control and Prevention (CDC) announced that it had identified for…
-
Patient with HIV achieved remission following stem cell transplant
On Jul. 27, 2022, City of Hope announced that a 66-year-old man who was diagnosed with HIV in…
-
Novavax Nuvaxovid COVID-19 vaccine granted provisional registration in Australia for use in adolescents aged 12 through 17
On Jul. 26, 2022, Novavax announced that the Australian Therapeutic Goods Agency had granted expanded approval for provisional…
-
Novavax announced expanded approval of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 in Japan
On Jul. 26, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had received expanded manufacturing and marketing approval…
-
CDC reported 2021-2022 flu season was relatively mild but longer than usual
On Jul. 22, 2022, the Centers for Disease Control and Prevention (CDC) released a MMWR report that summarized…
-
Genome of 6,000-year-old wild watermelon sequenced
On Jul. 22, 2022, a team of scientists announced they had sequenced the genome of a 6,000-year-old citrullus…
-
EMA Committee for Medicinal Products for Human Use recommended use of the Moderna COVID-19 booster in adolescents (12-17 years)
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
-
CHMP adopted positive opinion recommending Vekluryﾮ (Remdesivir) receive full Marketing Authorization for teatment of patients with COVID-19
On Jul. 22, 2022, Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of…
-
USDA confirmed highly pathogenic Avian influenza in Florida
On Jul. 22, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
-
New York State Department of Health and Rockland County Department of Health alerted public to case of polio
On Jul. 21, 2022, The New York State Department of Health confirmed that a case of paralytic poliomyelitis…
-
Vaccine-induced immune response to Omicron wanes substantially over time
On Jul. 19, 2022, the NIH announced that although COVID-19 booster vaccinations in adults elicit high levels of…
-
Novavax announced expanded agreement with SK bioscience to manufacture COVID-19 vaccine with Omicron variant
On Jul. 19, 2022, Novavax announced that it had signed agreements with its partner, SK bioscience, for the…
-
U.S. CDC endorsed Advisory Committee on Immunization Practices’ recommendation for Novavax COVID-19 vaccine
On Jul. 19, 2022, Novavax announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee…
-
Yale-developed vaccine offers superior protection against Omicron variants
On Jul. 19, 2022, Yale scientists announced they had developed a novel Omicron-specific mRNA vaccine that offers superior…
-
Gilead Sciences signed joint procurement agreement with the European Commission for Vekluryﾮ (Remdesivir)
On Jul. 19, 2022, Gilead Sciences and the European Commission announced a new joint procurement agreement (JPA) that…
-
Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
-
Ghana declared first-ever outbreak of Marburg virus disease
On Jul. 17, 2022, Ghana announced the preliminary finding of two cases of Marburg virus disease and if…
-
COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades
On Jul. 15, 2022, The largest sustained decline in childhood vaccinations in approximately 30 years has been recorded…
-
Aegis Sciences begin Monkeypox testing, increasing nationwide testing capacity
On Jul 14. 2022, Aegis Sciences announced it is was authorized to begin testing for monkeypox using the…
-
Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
-
Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17
On Jul. 13, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
-
Quest Diagnostics launched Monkeypox virus testing
On Jul 13. 2022, Quest Diagnostics announced the nationwide availability of the company’s lab-developed molecular diagnostic test to…
-
Quest Diagnostics launched Monkeypox virus testing
On Jul. 13, 2022, Quest Diagnostics announced that it had announced the nationwide availability* of the company’s lab-developed…
-
U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for individuals aged 18 and over
On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from…
-
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
